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Abstract:
Novel voriconazole-loaded solid lipid nanoparticles (VRC-SLNs) were prepared via probeultrasonication method, and the resultant nanoparticles were tested on A. fumigatus.
Voriconazole-loaded solid lipid nanoparticles were prepared using the probe ultrasonication technique. Photon correlation spectroscopy (PCS) was used to determine the average particle size and zeta potential of SLN formulations. Transmission electron microscopy was also used to determine the morphology of solid lipid nanoparticles. To determine MIC for all SLN A C C E P T E D M A N U S C R I P T formulations against strains of Aspergillus the Clinical and Laboratory Standards Institute guidelines was followed. The results showed that SLNs containing voriconazole exhibited almost spherical shape with a diameter and zeta potential of 286.6± 4.7nm and -15 ± 4.1 mV respectively. This novel formulation of VRC led to a significant reduction in MICs for all Aspergillus either VRC-susceptible or VRC-resistant isolates (P < 0.05). The MIC50 drug concentration was obtained as 0.015 μg/ml for both VRC-susceptible strains of A. fumigates while it was 0.25 μg/ml against VRC (p<0.05). VRC-resistant strains showed a MIC50 of 0.015 μg/ml as well. These novel drug formulations may increase the bioavailability through an increase in the dissolution rate of voriconazole. This study showed, for the first time, VRC-SLNs can be employed as an effective delivery systems for VRC on A. fumigatus isolates. Aspergillus is a saprophytic conidial mold isolated abundantly from soil, construction dust and hospitals (1, 2) which causes a broad spectrum of pulmonary aspergillosis (allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA) and invasive pulmonary aspergillosis (IPA)) (3).
Voriconazole (VRC) is used as the first-line treatment for invasive aspergillosis [(4)] and is available in oral and intravenous formulations. Voriconazole is a second-generation broadspectrum triazole that inhibits the cytochrome P450-dependent enzyme lanosterol 14 alphademethylase, and subsequently, interrupts the essential step for ergosterol biosynthesis in the fungal cell [ (5)]. Apart from the clinical implications of resistance, exposure of the fungus to azoles in the environment is the second route for induction of resistance [(6) ]. In a recent international surveillance study, the prevalence rate of azole-resistant A. fumigatus isolates was determined to be 3.2% [(7)]. Moreover, it has been reported that the prevalence of azoleresistant A. fumigatus in Iran has gone up remarkably from 3.3% to 6.6% [(8) ]. Therefore, designing new antifungal agents/formulations or novel drug delivery systems is highly required to introduce a new phase in the management of invasive aspergillosis.
Generally, solid lipid nanoparticles (SLNs) contains biodegradable lipid which could be in a solid form at both room and body temperatures and their particle size varies between 50 and 1000 nm [(9, 10)]. They have numerous advantages such as drug protection against harsh environmental situations, ease of large scale production using high pressure homogenization technique, biocompatibility, and biodegradability (11) . This carrier can be administered through general routes, which can transport the drug to the target site. Biodegradable lipid matrix, high
drug loading, increased drug stability, controlled drug release, and enhanced penetration of drugs into the skin or any other target are some of the other advantages of SLNs [(12, 13) ].
Therefore, the aim of the present study was to develop a new drug delivery system using solid lipid nanoparticles loaded with VRC (VRC-SLNs) prepared by high-shear homogenization and ultrasonication methods. Large-scale productions of lipid nanoparticles are mainly obtained by high pressure homogenization technique (14) . The influence of some formulation variables on the characteristics of the VRC-SLNs was also investigated. Drug susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) M38-A2 protocol for strains both resistant and susceptible to VRC.
Material and method
Voricnazole (Fanavaran Daroui Hakim, Tehran-Iran), Compritol®888 ATO (CO), Lipocire, Precirol®ATO5 and stearic acid (all were supplied by Gattefossé;Saint-Priest, Cedex, France), spans 80, 60 , Tween 80, sodium acetate, acetic acid, methanol, Sabouraud dextrose agar (SDA), RPMI medium (Merck, Germany ) and morpholinepropanesulfonic acid (MOPS) from Sigma Chemical Co., St. Louis, MO (USA) were used. All other reagents and solvents used in the current study were either of analytical or HPLC grades.
Screening of lipids
The screening of lipids was performed by evaluating the solubility of voriconazole, VRC with varying concentrations ranging from 10 to 25% w/w with regard to lipid mass in different lipids (Compritol®888 ATO (CO), Lipocire, Precirol®ATO 5 and stearic acid). The physical mixtures of lipid and VRC were heated to 85ºC followed by the examination of the formulations to see
which lipid or lipid combinations could dissolve the drug completely. Those lipids were able to dissolve the drug completely were selected to make SLNs.
Preparation of VRC-SLNs
The solid lipid nanoparticles loaded with VRC (VRC-SLNs) was prepared by high-shear homogenization followed by probe ultrasonication technique which has been published previously [ (15) 
Characterization of VRC-SLNs
2.3.1 Determination of particle size and zeta potentials
The Zeta Sizer Nano ZS (Malvern Instruments, UK) was employed to determined the average particle size and zeta potential of SLNs at 25 ºC at a fixed angle of 90º. The results are the means and standard deviations of at least three determinations.
Morphology measurement
In order to evaluate the morphology of drug particles field emission scanning electron microscope (FESEM, HITACHI S-4160, and U.S.A) was used. A drop of suspension was located on double-sided carbon tape and dried at 25•C for 24 h followed by sputter coated with gold for 40 s before examination.
Antifungal susceptibility testing for VRC-SLN

Isolates
A total of 62 clinical and environmental isolates were employed. Clinical isolates (n=83, 3.18%) had been obtained from the lower respiratory tract, sinus, cerumen, nails. Biopsy samples via routine diagnostic procedures at hospital laboratories and environmental isolates (n=42, 8313%) had been collected from the soil of gardens surrounding the hospitals and indoor air of hospital wards. Cultures were prepared on a Sabouraud dextrose agar plate (SDA; Difco), and incubated at 30 ºC for 72 h.
Antifungal agents
In order to determine antifungal susceptibility of nanoparticle formulations and pure VRC, the test (AFST) was carried. To this end, the drug solution in DMSO was prepared and then a two- A C C E P T E D M A N U S C R I P T
Statistical analysis
In order to find out the differences between various groups, an ANOVA test (SPSS version 18) was performed followed by Dunnett's test. In addition, the Mann-Whitney U test was also applied to test the significant reduction in the MIC caused by VRC-SLNs. The differences were considered statistically significant at P < 0.05. All of the results reported here were the mean and standard deviation of at least 3 determinations.
Results
Screening of lipids
The very first steps in selecting the lipids for the formulation of the lipid nanoparticles, was the evaluation of the solubility of the drug in the lipid material. Four lipids were chosen and listed in Table 1 . The results showed that no drug crystals can be seen in the sample containing either stearic acid or Compritol. Table 2 presents the particle sizes, zeta potential of the developed SLNs. The results showed that the particle sizes of all SLNs prepared in the current study are in nano-sized range. As VRCSLNs 4 produced the smallest particle size (286.6 nm) and relatively good zeta potential (-15), therefore it was selected as the best formulation compared to other SLN manufactured in this research. Figure 1 represents the morphology of the best SLN. (Table 3 and Fig 2) .
Characterization of SLNs
Antifungal susceptibility testing
A C C E P T E D M A N U S C R I P T
Discussion
VRC is classified as a class II drug according to the Biopharmaceutical Classification System (BCS). The drug's bioavailability is relatively low, and its aqueous solubility is poor at physiological pH, reducing its dissolution rate. Therefore, for this drug to have a maximum therapeutic effect, higher bioavailability and dissolution rates are required [ (17)]. To enhance the solubility of VRC and overcome the limitations mentioned above, SLNs can be utilized. SLNs are safe carriers and have low toxicity levels, which is due to their matrix being composed of biodegradable physiological lipids. By using SLNs, lyophilization becomes possible and the bioavailability of poorly soluble molecules such as VRC is improved [(5, 18) ].
The existing reports demonstrated that SLNs systems can be used to upload azole agents [(19-21) ]; however, to the best of our knowledge, there is not much research and data published on the delivery of VRC using SLNs [ (5, 22, 23) ]. There are studies focused on the effective ocular delivery of VRC-SLNs (24, 25) but they did not investigated their direct influence on the drug delivery to the fungal cells. It was important to extend the study to see whether VRC can be loaded on SLN and also if it is possible to obtain the desirable properties for VAC-SLNs. Having very small particle size for lipids in SLN formulations can guarantee the close contact between particles and the target tissue, which might increase drug penetration [ (13)]. The size of lipid matrices may also enable sustained drug release. The assessment of the most suitable lipid carriers to prepare stable nanoparticles was optimised as the first step. As shown in Table 1 Table 1 failed to dissolve VRC completely. It could be clearly observed from Table 2 that the average particle size and zeta potential decreased in VRC-SLN4 using stearic acid as solid lipid and Span 80 as lipophilic surfactant (P > 0.05). It has been shown that the presence of Span 80 can cause a greater drop in the interfacial tension in VRC-SLNs ( formulation 4), leading to a more homogenized dispersion with smaller particles and lower zeta potential. These results were in agreement with previously reported studies. It has been reported that lipid type, emulsifier type and their concentrations are parameters that were recognized as major factors influencing the size of solid lipid nanoparticles (26, 27) . In the present study, an effective formulation of VRC-SLNs was obtained. As the surfactant can influence the size of These photomicrographs demonstrated that the particles had smooth surfaces and were almost spherical in shape.
It was interesting to note that when VRC-SLNs were applied the values of the MICs decreased significantly compared to VRC on its own, suggesting that the therapeutic dose could be reduced hence the risk of adverse drug effects may be decreased. One possible explanation for the antifungal susceptibility results is the mechanism responsible for the drug resistance recognized in pathogenic fungi [(31, 32) ]. The mechanism of drug resistance can happen in three distinct ways, namely reduction of drug concentration that can happen to drug efflux, change in the drug target, and mutation in genome sequence [(33, 34) ]. The most important mechanism, which leads to a decrease in drug concentration, is efflux. Several efflux transport systems exist including ABC transporters and MFS transporters that are found in A. fumigates [(35) ].
The overexpression of pleiotropic drug resistance (PDR) efflux pumps is a major mechanism of drug resistance for azole antifungals [26] . The efflux pumps are members of ATP-binding cassette (ABC) transporters superfamily. Strategies to overcome the problem of PDR includes the design of specific inhibitors of these efflux pumps, or design of antifungal molecules with suitable shields to prevent binding to the efflux pumps. In this study, we benefited from
nanoscaled safeguard of VRC-SLNs that protect the drug from being pumped out by transporter proteins. Moreover, penetration of drug into fungal cells may be facilitated due to the hydrophobic surface of VRC-SLNs.
Conclusion
Voriconazole solid lipid nanoparticles were successfully prepared. These novel delivery systems could face A. fumigatus strains that an exhibit different susceptibility to the conventional formulation of VRC was investigated. The results proved that these novel drug formulations may increase the bioavailability and dissolution rate of VRC to enhance the performance of the formulations.
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